Price
814.95
-0.74%52W Range
Market Cap
₹15,938.94 Cr
Traded: ₹58.12 Cr (0.36%) 0.0x
Free Float: ₹4,839.06 Cr (1.20% of FF traded)
Volume · 60D trend
7.1 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | +8.0% | +18.0% | +109.0% | -- | +117.0% | Accelerating |
| Sales | +8.0% | +11.0% | +14.0% | -- | +28.0% | Accelerating |
| ROE | +6.0% | +4.0% | +6.0% | -- | -- | Stable |
| Return | +10.0% | +18.0% | +58.0% | +67.0% | -- | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 466 | 437 | 410 | 370 | 321 | 331 | 319 | 344 | 293 | 292 | 287 | 313 | 260 | 264 | 262 | 263 |
| Expenses | 330 | 317 | 296 | 262 | 231 | 252 | 239 | 258 | 222 | 222 | 222 | 255 | 214 | 227 | 231 | 253 |
| Operating Profit | 136 | 120 | 114 | 108 | 91 | 79 | 81 | 86 | 70 | 70 | 65 | 58 | 46 | 37 | 31 | 10 |
| OPM % | 29.0% | 27.0% | 28.0% | 29.0% | 28.0% | 24.0% | 25.0% | 25.0% | 24.0% | 24.0% | 23.0% | 19.0% | 18.0% | 14.0% | 12.0% | 4.0% |
| Other Income | 9 | 45 | -13 | 2 | 6 | -21 | 2 | 5 | 10 | 9 | 2 | 2 | 2 | 2 | 3 | 4 |
| Interest | 12 | 14 | 11 | 16 | 19 | 14 | 12 | 26 | 24 | 24 | 26 | 23 | 18 | 18 | 18 | 13 |
| Depreciation | 35 | 31 | 30 | 30 | 29 | 29 | 29 | 28 | 27 | 27 | 27 | 28 | 27 | 26 | 24 | 23 |
| Profit Before Tax | 98 | 120 | 61 | 64 | 50 | 15 | 42 | 37 | 29 | 28 | 14 | 9 | 3 | -4 | -8 | -22 |
| Tax % | -3.0% | 10.0% | 27.0% | 32.0% | 5.0% | 5.0% | 24.0% | 51.0% | 51.0% | 12.0% | 67.0% | 83.0% | 64.0% | 90.0% | -13.0% | -17.0% |
| Net Profit | 101 | 108 | 45 | 44 | 47 | 15 | 32 | 18 | 14 | 24 | 5 | 2 | 1 | -8 | -7 | -19 |
| Exceptional Items | -- | 25 | -13 | 0 | 0 | -31 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 5.2 | 5.5 | 2.3 | 2.3 | 2.4 | 0.7 | 1.6 | 0.9 | 0.7 | 1.4 | 0.3 | 0.1 | 0.1 | -0.5 | -0.4 | -1.1 |
| Sales Growth (YoY) | 45.2% | 32.0% | 28.5% | 7.6% | 9.6% | 13.4% | 11.2% | 9.9% | 12.7% | 10.6% | 9.5% | 19.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 6.6% | 6.6% | 10.8% | 15.3% | -3.0% | 3.8% | -7.3% | 17.4% | 0.3% | 1.7% | -8.3% | 20.4% | -1.5% | 0.8% | -0.4% | -- |
| OP Growth (YoY) | 49.5% | 51.9% | 40.7% | 25.6% | 30.0% | 12.9% | 24.6% | 48.3% | 52.2% | 89.2% | 109.7% | 480.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 13.3% | 5.3% | 5.6% | 18.7% | 15.2% | -2.5% | -5.8% | 22.9% | 0.0% | 7.7% | 12.1% | 26.1% | 24.3% | 19.4% | 210.0% | -- |
| Profit Growth (YoY) | -- | 148.0% | 70.0% | 146.0% | 234.0% | 65.0% | 594.0% | 1014.0% | 1092.0% | 359.0% | 169.0% | 109.0% | 39.0% | -127.0% | -169.0% | -230.0% |
| EPS Growth (YoY) | 115.0% | 644.6% | 40.7% | 144.6% | 233.3% | -47.5% | 523.1% | 922.2% | 928.6% | 406.5% | 168.4% | 108.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -6.3% | 141.7% | 1.3% | -6.3% | 224.3% | -54.3% | 76.1% | 27.8% | -48.9% | 442.3% | 188.9% | 28.6% | 115.2% | -21.1% | 64.5% | -- |
| OP Margin | 29.2% | 27.5% | 27.8% | 29.2% | 28.4% | 23.9% | 25.4% | 25.0% | 23.9% | 24.0% | 22.6% | 18.5% | 17.7% | 14.0% | 11.8% | 3.8% |
| Net Margin | 21.7% | 24.7% | 11.0% | 11.9% | 14.6% | 4.5% | 10.0% | 5.2% | 4.8% | 8.2% | 1.7% | 0.6% | 0.4% | -3.0% | -2.7% | -7.2% |
| Material Cost % | -- | 32.5% | 32.5% | 28.5% | 24.8% | 31.6% | 28.5% | 35.5% | 31.8% | 33.3% | 33.7% | 40.2% | 33.9% | 34.0% | 40.2% | 44.3% |
| Employee Cost % | -- | 19.8% | 20.3% | 22.4% | 25.4% | 21.4% | 23.0% | 22.1% | 24.7% | 22.8% | 24.1% | 23.4% | 28.0% | 27.3% | 26.1% | 28.0% |
| P/S | 9.47 | 8.20 | 6.48 | 4.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 53.62 | 51.82 | 61.88 | 48.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.15 | 4.86 | 3.81 | 2.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Dispatch of letter to shareholders whose e-mail addresses are not registered with Company/ Registrar & Transfer Agent/ Depository Participants.
Disclosure under Reg.30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Newspaper Publication
Annual Report of Shilpa Medicare Limited for the FY 2025-26
39th Annual General Meeting Notice
Q1FY27 earnings conference call transcript
Unaudited standalone and consolidated Financial Results for the Quarter ended 30 June 2026
The record date for determining the shareholders entitled for payment of final dividend for FY 2025-26, if declared at the 39th AGM is Friday, 4th September 2026.
Unaudited Financial Results for the Quarter ended 30 June 2026
Credit Rating
Resignation of Dr. Sridevi Khambhampaty, as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, material subsidiary of Shilpa Medicare Limited.
Intimation of Credit Rating
Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018
Shilpa Biologicals Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited enters into a Co-development and supply agreement with Orion Corporation, Finland
Newspaper Publication
Intimation of Closure of Trading Window
Shilpa Biologicals Pvt Ltd, a material subsidiary of Shilpa Medicare Ltd and M/s Sartorius Stedim India Pvt Ltd have entered into a settlement agreement
Shilpa Medicare Limited has informed the exchange about the copy of news paper publication.
Press Release on announcement of commissioning of a state-of-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility by Shilpa Biologicals Private Limited, a material subsidiary of ....
Scrutinizers Report along with Voting Results of Postal Ballot
USFDA Inspection of Shilpa Medicare Limited at Unit VI, Dabaspet, Bengaluru
Annual Secretarial Compliance Report for the financial year 2025-26
Transcript of the Q4FY26 Conference call
Postal Ballot notice published in news paper.
Postal Ballot notice published in newspaper
Analyst/Investor Call -Call Recording
Notice of Postal Ballot
Investor Presentation for the period - Q4FY26
Financial Results
Outcome of the Board Meeting
The schedule of Q4- FY26 Earnings Conference Call, which is to be held on Friday, May 22, 2025, at 16.00 hrs.
Shilpa Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve we hereby wish to inform you ....
Appointment of Dr. Vellaian Karuppiah as Chief Operating Officer (COO)- Formulations - Senior Managerial Personnel.
Retirement of Senior Managerial Personnel (SMP)
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Submission of confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31 March 2026.
Intimation of Closure of Trading Window under the SEBI (Prohibition of Insider Trading) Regulation, 2015 for the fourth quarter and year ended 31 March, 2026.
Intimation of certified true copy of NCLT Order approving the Scheme of amalgamation.
NCLT order on merger of Shilpa Therapeutics Private Limited a wholly owned subsidiary with Shilpa Media Limited.
Press release
Newspaper advertisement - Special Window for Transfer and Dematerialisation of Physical shares.
Revised attachment to Annexure - 1, on Execution of Agreement with NXI Therapeutics AG
Transcript of the Q3-FY26 Conference call
Outcome of the Board Meeting of the Company for the third quarter and nine months ended 31 December 2025 held on 06 February 2026.
Announcement under Regulation 30 (LODR)-Investor Presentation
Integrated financials for third quarter and nine months ended 31 December 2025
Announcement under regulation 30 (LODR) - Investor Presentation
Shilpa announces the filing of ROTIGOTINE Transdermal System, USP, its First Transdermal patch ANDA to the USFDA
Analyst/Investor Call -Call Recording
Shilpa Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve We hereby wish to inform you ....
Annual Reports
14Credit Ratings
6Concalls
31Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jul 2024
31 Jul 2024May 2024
31 May 2024May 2024
31 May 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Feb 2022
28 Feb 2022Oct 2021
31 Oct 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Held by ETFs
2 ETFs hold SHILPAMED · sorted by weight
Held by Mutual Funds
18 schemes hold SHILPAMED · sorted by weight